318 related articles for article (PubMed ID: 23485770)
1. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.
Brinton LA; Felix AS; McMeekin DS; Creasman WT; Sherman ME; Mutch D; Cohn DE; Walker JL; Moore RG; Downs LS; Soslow RA; Zaino R
Gynecol Oncol; 2013 May; 129(2):277-84. PubMed ID: 23485770
[TBL] [Abstract][Full Text] [Related]
2. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
3. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis.
Reid-Nicholson M; Iyengar P; Hummer AJ; Linkov I; Asher M; Soslow RA
Mod Pathol; 2006 Aug; 19(8):1091-100. PubMed ID: 16648864
[TBL] [Abstract][Full Text] [Related]
4. Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial.
Felix AS; Scott McMeekin D; Mutch D; Walker JL; Creasman WT; Cohn DE; Ali S; Moore RG; Downs LS; Ioffe OB; Park KJ; Sherman ME; Brinton LA
Gynecol Oncol; 2015 Oct; 139(1):70-6. PubMed ID: 26341710
[TBL] [Abstract][Full Text] [Related]
5. Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers.
Pothuri B; Ramondetta L; Eifel P; Deavers MT; Wilton A; Alektiar K; Barakat R; Soslow RA
Gynecol Oncol; 2006 Dec; 103(3):948-51. PubMed ID: 16870239
[TBL] [Abstract][Full Text] [Related]
6. Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women.
Hagemann IS; Deng W; Zaino RJ; Powell MA; Gunderson Jackson C; Cosgrove C; Mathews C; Pearl ML; Waggoner S; Ghebre R; Lele S; Guntupalli S; Secord AA; Ioffe O; Rasty G; Singh M; Soslow R; Creasman W; Mutch DG
Gynecol Oncol; 2023 Oct; 177():38-45. PubMed ID: 37634258
[TBL] [Abstract][Full Text] [Related]
7. Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol.
Creasman WT; Ali S; Mutch DG; Zaino RJ; Powell MA; Mannel RS; Backes FJ; DiSilvestro PA; Argenta PA; Pearl ML; Lele SB; Guntupalli SR; Waggoner S; Spirtos N; Boggess JF; Edwards RP; Filiaci VL; Miller DS
Gynecol Oncol; 2017 Jun; 145(3):519-525. PubMed ID: 28392124
[TBL] [Abstract][Full Text] [Related]
8. Incidence and effects on mortality of venous thromboembolism in elderly women with endometrial cancer.
Rauh-Hain JA; Hariton E; Clemmer J; Clark RM; Hall T; Boruta DM; Schorge JO; Del Carmen MG
Obstet Gynecol; 2015 Jun; 125(6):1362-1370. PubMed ID: 26000507
[TBL] [Abstract][Full Text] [Related]
9. The Growing Burden of Endometrial Cancer: A Major Racial Disparity Affecting Black Women.
Cote ML; Ruterbusch JJ; Olson SH; Lu K; Ali-Fehmi R
Cancer Epidemiol Biomarkers Prev; 2015 Sep; 24(9):1407-15. PubMed ID: 26290568
[TBL] [Abstract][Full Text] [Related]
10. Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.
Felix AS; Brasky TM; Cohn DE; Mutch DG; Creasman WT; Thaker PH; Walker JL; Moore RG; Lele SB; Guntupalli SR; Downs LS; Nagel C; Boggess JF; Pearl ML; Ioffe OB; Deng W; Miller DS; Brinton LA
Int J Cancer; 2018 Mar; 142(6):1102-1115. PubMed ID: 29063589
[TBL] [Abstract][Full Text] [Related]
11. Type I and II endometrial cancers: have they different risk factors?
Setiawan VW; Yang HP; Pike MC; McCann SE; Yu H; Xiang YB; Wolk A; Wentzensen N; Weiss NS; Webb PM; van den Brandt PA; van de Vijver K; Thompson PJ; ; Strom BL; Spurdle AB; Soslow RA; Shu XO; Schairer C; Sacerdote C; Rohan TE; Robien K; Risch HA; Ricceri F; Rebbeck TR; Rastogi R; Prescott J; Polidoro S; Park Y; Olson SH; Moysich KB; Miller AB; McCullough ML; Matsuno RK; Magliocco AM; Lurie G; Lu L; Lissowska J; Liang X; Lacey JV; Kolonel LN; Henderson BE; Hankinson SE; Håkansson N; Goodman MT; Gaudet MM; Garcia-Closas M; Friedenreich CM; Freudenheim JL; Doherty J; De Vivo I; Courneya KS; Cook LS; Chen C; Cerhan JR; Cai H; Brinton LA; Bernstein L; Anderson KE; Anton-Culver H; Schouten LJ; Horn-Ross PL
J Clin Oncol; 2013 Jul; 31(20):2607-18. PubMed ID: 23733771
[TBL] [Abstract][Full Text] [Related]
12. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
13. Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure.
Tergas AI; Buell-Gutbrod R; Gwin K; Kocherginsky M; Temkin SM; Fefferman A; Lengyel E; Yamada SD
Gynecol Oncol; 2012 Nov; 127(2):316-20. PubMed ID: 22835717
[TBL] [Abstract][Full Text] [Related]
14. Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence.
Brasky TM; Felix AS; Cohn DE; McMeekin DS; Mutch DG; Creasman WT; Thaker PH; Walker JL; Moore RG; Lele SB; Guntupalli SR; Downs LS; Nagel CI; Boggess JF; Pearl ML; Ioffe OB; Park KJ; Ali S; Brinton LA
J Natl Cancer Inst; 2017 Mar; 109(3):1-10. PubMed ID: 28376204
[TBL] [Abstract][Full Text] [Related]
15. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 1999 Sep; 74(3):385-94. PubMed ID: 10479498
[TBL] [Abstract][Full Text] [Related]
16. Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior.
Bansal N; Herzog TJ; Seshan VE; Schiff PB; Burke WM; Cohen CJ; Wright JD
Obstet Gynecol; 2008 Jul; 112(1):64-70. PubMed ID: 18591309
[TBL] [Abstract][Full Text] [Related]
17. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
[TBL] [Abstract][Full Text] [Related]
18. Can the apparent diffusion coefficient differentiate the grade of endometrioid adenocarcinoma and the histological subtype of endometrial cancer?
Yan B; Zhao T; Liang X; Niu C; Ding C
Acta Radiol; 2018 Mar; 59(3):363-370. PubMed ID: 28696169
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
20. Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers.
Altman AD; Ferguson SE; Atenafu EG; Köbel M; McAlpine JN; Panzarella T; Lau S; Gien LT; Gilks B; Clarke B; Cameron A; Nelson G; Han G; Samouëlian V; Ho TC; Louie K; Bernardini MQ
Gynecol Oncol; 2015 Nov; 139(2):268-74. PubMed ID: 26352641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
